A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Phase 1 Completed 33 enrolled Gilead Sciences

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.

Timeline

Start: 2013-03
Primary completion: 2013-08
Completion: 2013-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	velpatasvir	Other / unclassified	100 mg	—

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Summary

Timeline

Drugs

Indications